Healthcare provider profile · identity verified

Pamela Sharp, FNP

Nurse Practitioner · YUMA, AZ · NPI 1881003515

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	441	138
Lisinopril	Lisinopril	409	136
Metformin Hcl	Metformin Hcl	277	93
Amlodipine Besylate	Amlodipine Besylate	266	79
Glipizide Er	Glipizide	248	75
Levothyroxine Sodium	Levothyroxine Sodium	230	64
Losartan Potassium	Losartan Potassium	222	66
Gabapentin	Gabapentin	201	63
Omeprazole	Omeprazole	173	60
Fluticasone Propionate	Fluticasone Propionate	170	80
Pantoprazole Sodium	Pantoprazole Sodium	120	54
Hydrochlorothiazide	Hydrochlorothiazide	119	41
Ibuprofen	Ibuprofen	110	48
Metoprolol Tartrate	Metoprolol Tartrate	105	30
Tamsulosin Hcl	Tamsulosin Hcl	104	31
Simvastatin	Simvastatin	93	29
Alendronate Sodium	Alendronate Sodium	90	33
Meclizine Hcl	Meclizine Hcl	89	39
Pravastatin Sodium	Pravastatin Sodium	77	24
Carvedilol	Carvedilol	71	21
Trazodone Hcl	Trazodone Hcl	70	25
Tramadol Hcl	Tramadol Hcl	63	14
Januvia	Sitagliptin Phosphate	60	22
Diclofenac Sodium	Diclofenac Sodium	59	38
Rosuvastatin Calcium	Rosuvastatin Calcium	59	22
Meloxicam	Meloxicam	58	24
Famotidine	Famotidine	57	30
Sertraline Hcl	Sertraline Hcl	55	18
Tizanidine Hcl	Tizanidine Hcl	55	29
Clopidogrel	Clopidogrel Bisulfate	54	17
Furosemide	Furosemide	53	22
Atenolol	Atenolol	52	11
Azelastine Hcl	Azelastine Hcl	51	27
Albuterol Sulfate Hfa	Albuterol Sulfate	47	20
Ezetimibe	Ezetimibe	47	16
Lantus	Insulin Glargine,hum.Rec.Anlog	47	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	46	17
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	45	16
Jardiance	Empagliflozin	45	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	45	17
Potassium Chloride	Potassium Chloride	37	12
Glipizide	Glipizide	36	suppressed
Clonidine Hcl	Clonidine Hcl	34	15
Buspirone Hcl	Buspirone Hcl	33	13
Montelukast Sodium	Montelukast Sodium	33	suppressed
Eliquis	Apixaban	32	11
Hydroxyzine Hcl	Hydroxyzine Hcl	31	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	12
Farxiga	Dapagliflozin Propanediol	30	suppressed
Tradjenta	Linagliptin	30	12
Ondansetron Odt	Ondansetron	28	17
Nifedipine Er	Nifedipine	27	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	26	16
Allopurinol	Allopurinol	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	12
Metoprolol Succinate	Metoprolol Succinate	25	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Gemfibrozil	Gemfibrozil	23	suppressed
Finasteride	Finasteride	22	suppressed
Naproxen	Naproxen	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	17
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Proctosol-Hc	Hydrocortisone	19	11
Trulicity	Dulaglutide	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	16
Spironolactone	Spironolactone	18	suppressed
Estradiol	Estradiol	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	16	suppressed
Donepezil Hcl	Donepezil Hcl	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Valsartan	Valsartan	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Methylprednisolone	Methylprednisolone	13	12
Constulose	Lactulose	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Cephalexin	Cephalexin	11	11
Fluconazole	Fluconazole	11	11
Procto-Med Hc	Hydrocortisone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error